Genomics is a rapidly growing field, and hedge funds have taken notice. According to a recent report by Insider Monkey, 11 genomics stocks have caught the attention of hedge funds, making them top picks for investors. So what makes these stocks stand out and why should retail investors pay attention?
First on the list is Exact Sciences Corporation (EXAS), a company that specializes in cancer screening tests. Its stock has been on an upward trend in recent years, with a 5-year return of over 1000%. With a growing need for early cancer detection, Exact Sciences is in a prime position for continued success.
Another top pick is Invitae Corporation (NVTA), a genetic testing company that has seen a 10-year return of over 500%. With the rise of personalized medicine and the increasing use of genetic testing, Invitae is poised for even more growth in the coming years.
One standout stock on the list is Vertex Pharmaceuticals Incorporated (VRTX), which has a 5-year return of over 400%. Known for its treatments for cystic fibrosis, Vertex has a strong pipeline and potential for future growth.
Other notable companies on the list include CRISPR Therapeutics AG (CRSP), Bio-Rad Laboratories, Inc. (BIO), and Editas Medicine, Inc. (EDIT). All of these companies have made significant strides in the field of genomics and have the potential to yield high returns for investors.
While hedge funds are known for their savvy investment strategies, it’s important for retail investors to do their own research and make informed decisions when it comes to investing in genomics stocks. However, with the rapid advancements in this field and the potential for significant growth, these 11 stocks are definitely worth keeping an eye on.